Endo Pharma (ENDP) Tops Q4 EPS by 8c; Guides FY12 EPS, Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Price: $0.29 --0%
Financial Fact:
Total consolidated income before income tax: -761.68M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Total consolidated income before income tax: -761.68M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q4 EPS of $1.40, $0.08 better than the analyst estimate of $1.32. Revenue for the quarter came in at $803.4 million versus the consensus estimate of $802.9 million.
Endo Pharmaceuticals Holdings sees FY2012 EPS of $5.00-$5.20, versus the consensus of $5.46. Endo Pharmaceuticals Holdings sees FY2012 revenue of $3.15-$3.30 billion, versus the consensus of $3.23 billion.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Endo Pharmaceuticals Holdings sees FY2012 EPS of $5.00-$5.20, versus the consensus of $5.46. Endo Pharmaceuticals Holdings sees FY2012 revenue of $3.15-$3.30 billion, versus the consensus of $3.23 billion.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Top restaurant stocks to watch, according to Raymond James
- Truist names top clean energy stocks to watch ahead of Q3 earnings season
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
